EUVIMEDEUVIMED entdecken
Open Access

EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression

Arthur R Wolin iD, Melanie Y Vincent, Taylor Hotz, Stephen C Purdy iD, Sheera R Rosenbaum iD, Connor J Hughes iD, Jessica Y Hsu, Michael U J Oliphant, Brock Armstrong, Veronica Wessells, Marileila Varella-Garcia iD, Matthew D Galbraith iD und 10 weitere

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noad128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Arthur R Wolin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Medulloblastoma is the most common pediatric brain malignancy. Patients with the Group 3 subtype of medulloblastoma (MB) often exhibit MYC amplification and/or overexpression and have the poorest prognosis. While Group 3 MB is known to be highly dependent on MYC, direct targeting of MYC remains elusive.

Methods

Patient gene expression data were used to identify highly expressed EYA2 in Group 3 MB samples, assess the correlation between EYA2 and MYC, and examine patient survival. Genetic and pharmacological studies were performed on EYA2 in Group 3 derived MB cell models to assess MYC regulation and viability in vitro and in vivo.

Results

EYA2 is more highly expressed in Group 3 MB than other MB subgroups and is essential for Group 3 MB growth in vitro and in vivo. EYA2 regulates MYC expression and protein stability in Group 3 MB, resulting in global alterations of MYC transcription. Inhibition of EYA2 tyrosine phosphatase activity, using a novel small molecule inhibitor (NCGC00249987, or 9987), significantly decreases Group 3 MB MYC expression in both flank and intracranial growth in vivo. Human MB RNA-seq data show that EYA2 and MYC are significantly positively correlated, high EYA2 expression is significantly associated with a MYC transcriptional signature, and patients with high EYA2 and MYC expression have worse prognoses than those that do not express both genes at high levels.

Conclusions

Our data demonstrate that EYA2 is a critical regulator of MYC in Group 3 MB and suggest a novel therapeutic avenue to target this highly lethal disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaCerebellar NeoplasmsHumansChildCell Line, TumorProtein Tyrosine PhosphatasesTyrosineNuclear ProteinsIntracellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

EYA2Group 3 medulloblastomaMYC

Substanzen

Protein Tyrosine PhosphatasesTyrosineEYA2 protein, humanNuclear ProteinsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, Colorado, USA.
  • Molecular Biology Graduate Program, University of Colorado AMC, Aurora, Colorado, USA.
  • Cancer Biology Graduate Program, University of Colorado AMC, Aurora, Colorado, USA.
  • Pharmacology Graduate Program, University of Colorado AMC, Aurora, Colorado, USA.
  • Medical Scientist Training Program, University of Colorado AMC, Aurora, Colorado, USA.
  • Integrated Physiology Graduate Program, University of Colorado AMC, Aurora, Colorado, USA.

ORCID-Profile: Arthur R Wolin, Stephen C Purdy, Sheera R Rosenbaum, Connor J Hughes, Marileila Varella-Garcia, Matthew D Galbraith, Dong Wang, Sujatha Venkataraman, Etienne Danis, Joaquin M Espinosa, Daniel L Gustafson, Heide L Ford

Förderung

  • NINDS NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • NIH

Zitieren

APA

Wolin, A. R., Vincent, M. Y., Hotz, T., Purdy, S. C., Rosenbaum, S. R., Hughes, C. J., Hsu, J. Y., Oliphant, M. U. J., Armstrong, B., Wessells, V., Varella-Garcia, M., Galbraith, M. D., Pierce, A., Wang, D., Venkataraman, S., Danis, E., Veo, B., Serkova, N., Espinosa, J. M., …, & Ford, H. L. (2023). EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad128

Vancouver

Wolin AR, Vincent MY, Hotz T, Purdy SC, Rosenbaum SR, Hughes CJ, et al. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad128

BibTeX
@article{Wolin2023,
  author = {Wolin, Arthur R and Vincent, Melanie Y and Hotz, Taylor and Purdy, Stephen C and Rosenbaum, Sheera R and Hughes, Connor J and Hsu, Jessica Y and Oliphant, Michael U J and Armstrong, Brock and Wessells, Veronica and Varella-Garcia, Marileila and Galbraith, Matthew D and Pierce, Angela and Wang, Dong and Venkataraman, Sujatha and Danis, Etienne and Veo, Bethany and Serkova, Natalie and Espinosa, Joaquin M and Gustafson, Daniel L and Vibhakar, Rajeev and Ford, Heide L},
  title = {EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noad128}
}
Kostenlos starten →